Skip to main content
. 2016 Apr 5;32(1):85–94. doi: 10.3904/kjim.2014.175

Table 1.

Baseline characteristics

Characteristic CTEPH group (n = 15, 6.1%) Non-CTEPH group (n = 231, 93.9%) p value
Demographic characteristic
 Mean age, yr 70.8 ± 8.1 66.5 ± 12.7 0.190
 Male sex 6 (40.0) 92 (39.8) 0.989
 Body mass index 23.41 ± 2.81 24.13 ± 3.33 0.430
Past history, %
 History of operation 5 (33.3) 98 (42.4) 0.489
 Malignancy 4 (26.7) 69 (29.9) 1.000
 Bedridden state 3 (20.0) 69 (29.9) 0.563
 Stroke 3 (20.0) 29 (12.6) 0.423
 Chemotherapy 2 (13.3) 40 (17.3) 1.000
 Lung disease 5 (33.3) 37 (16.0) 0.084
 Spinal cord injury 1 (6.7) 8 (3.5) 0.438
 Hormone therapy 0 4 (1.7) 1.000
 Pregnancy/peripartum 0 2 (0.9) 1.000
 Hematologic disease 1 (6.7) 12 (5.2) 0.568
 Autoimmune disease 1 (6.7) 1 (0.4) 0.118
 Oral contraceptives 0 1 (0.4) 1.000
Symptoms at admission, %
 Dyspnea 12 (80.0) 143 (61.9) 0.181
 Chest pain 3 (20.0) 40 (17.3) 0.731
 Cough 0 13 (5.6) 1.000
 Hemoptysis 1 (6.7) 6 (2.6) 0.360
 Wheezing 1 (6.7) 4 (1.7) 0.272
 Syncope 0 9 (3.9) 1.000
 Leg pain 2 (13.3) 44 (19.0) 0.744
 Mental change 0 12 (5.2) 1.000
Vital sign
 Systolic blood pressure, mmHg 112.0 ± 20.1 111.1 ± 23.1 0.876
 Heart rate, bpm 90.5 ± 16.6 88.3 ± 19.3 0.668
 Respiratory rate, /min 19.9 ± 3.3 20.0 ± 2.9 0.922
 SaO2, % 92.9 ± 6.5 94.7 ± 5.9 0.334
Laboratory test
 Troponin I, ng/mL 0.02 (0.02–0.13) 0.03 (0.0–0.16) 0.600
 CK-MB, μg/L 1.91 (0.74–3.73) 1.71 (0.92–3.69) 0.898
 D-dimer, μg/mL 1.52 (0.24–3.36) 4.64 (2.47–7.58) 0.002
 BNP, pg/mL 231.0 (47.0–1,421.4) 158.0 (29.5–605.4) 0.353
APE-risk stratification, %
 Low risk group 2 (13.3) 94 (40.7) 0.074
 Intermediate risk group 12 (80) 116 (50.2)
 High risk group 1 (6.7) 21 (9.1)

Values are presented as mean ± SD, number (%), or median (interquartile range).

CTEPH, chronic thromboembolic pulmonary hypertension; SaO2, oxygen saturation; CK-MB, creatine kinase MB fraction; BNP, brain natriuretic peptide; APE, acute pulmonary embolism.